fda glp-1 compounding enforcement november 2025 is short-sighted on GLP-1s FDA Sends Warning Letters to

Although the FAERS database aids in detecting rare adverse events via spontaneous reporting, its propensity to overestimate unexpected adverse events linked to new therapies makes it inappropriate for comparative analysis of adverse event frequencies among pharmaceuticals

19 in 4.1% of patients receiving 1.2 mg and 6.7% of patients receiving 1.8 mg (LEAD-4)

February Is the Real Reset February offers something January cant: honesty

A ZEISS Key Opinion Leader, Mr Hove is a respected international speaker with five invited engagements across seven cities in 2026: ZEISS China tour (Changsha, Shanghai, and Hangzhou, April ZEISS APAC User Meeting) RCOphth Annual Congress May Manchester ZEISS EMEA User Meeting (Istanbul) ZEISS Lausanne User Meeting (Lausanne) European Society of Cataract and Refractive Surgeons Annual Congress (ESCRS, London) Speak to Our Consultant-Led Team If you take a GLP-1 medication and have noticed any change in your vision, do not wait to have it checked

Let's look at some of the clinical studies that back this up